A team of researchers from the University of Nottingham have received funding to explore the capabilities of quantum computing for developing new drugs for myotonic dystrophy.

Building on an initial award of over £1 ($1.3) million, a team of researchers from the University of Nottingham, with partners Phasecraft and QuEra Computing, are one of only eight successful teams worldwide to progress to the second phase of the Wellcome Leap $50 million supported challenge programme Quantum for Bio (Q4Bio).

The programme aims to accelerate applications of quantum computing to address pressing human health challenges.

The ‘Quantum computing for covalent inhibitors in drug discovery’ project is led by Professor Jonathan Hirst and Dr Katie Inzani from the University of Nottingham. The team brings together expertise from human health sciences and computational chemistry, to quantum algorithm development and quantum hardware.

One of the most promising applications of near-term quantum computers is accurately modelling systems where quantum mechanics plays a key role, such as in materials science, chemistry and even drug discovery.

The new project will demonstrate how of quantum computing and classical simulation methods van be harnessed to tackle the crucial task of drug discovery for myotonic dystrophy.

Myotonic dystrophy is a genetic condition that causes progressive muscle weakness and wasting and often affects the electrical conduction system of the heart, breathing and swallowing muscles, bowels, lens of the eye and brain.

Jonathan Hirst, a Royal Academy of Engineering Chair in Emerging Technologies and Professor of Computational Chemistry at the University, said: “We are working towards the ambitious goal of developing and utilising this fast-developing technology to help advance the treatment of a dreadful disease.”

Diana Spencer, Senior Digital Content Editor, DDW